Published in Immunol Invest on January 01, 2010
Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection. Am J Respir Crit Care Med (2010) 1.03
Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediators Inflamm (2015) 0.97
The helminth product, ES-62, protects against airway inflammation by resetting the Th cell phenotype. Int J Parasitol (2013) 0.93
Mfge8 suppresses airway hyperresponsiveness in asthma by regulating smooth muscle contraction. Proc Natl Acad Sci U S A (2012) 0.92
Update on anticytokine treatment for asthma. Biomed Res Int (2013) 0.92
Opposite effects of mepyramine on JNJ 7777120-induced amelioration of experimentally induced asthma in mice in sensitization and provocation. PLoS One (2012) 0.87
Anti-HMGB1 neutralizing antibody ameliorates neutrophilic airway inflammation by suppressing dendritic cell-mediated Th17 polarization. Mediators Inflamm (2014) 0.85
Cyclooxygenase-2 inhibits T helper cell type 9 differentiation during allergic lung inflammation via down-regulation of IL-17RB. Am J Respir Crit Care Med (2013) 0.82
Role of T follicular helper cells and their associated molecules in the pathogenesis of chronic hepatitis B virus infection. Exp Ther Med (2012) 0.82
Asthma increases susceptibility to heterologous but not homologous secondary influenza. J Virol (2014) 0.82
Conditioning of naive CD4(+) T cells for enhanced peripheral Foxp3 induction by nonspecific bystander inflammation. Nat Immunol (2016) 0.81
Immunophenotyping of circulating T helper cells argues for multiple functions and plasticity of T cells in vivo in humans--possible role in asthma. PLoS One (2012) 0.80
Hyperoxia promotes polarization of the immune response in ovalbumin-induced airway inflammation, leading to a TH17 cell phenotype. Immun Inflamm Dis (2015) 0.78
A Recombinant DNA Plasmid Encoding the sIL-4R-NAP Fusion Protein Suppress Airway Inflammation in an OVA-Induced Mouse Model of Asthma. Inflammation (2016) 0.77
p-STAT6, PU.1, and NF-κB are involved in allergen-induced late-phase airway inflammation in asthma patients. BMC Pulm Med (2015) 0.76
Inactivated Mycobacterium phlei inhalation ameliorates allergic asthma through modulating the balance of CD4+CD25+ regulatory T and Th17 cells in mice. Iran J Basic Med Sci (2016) 0.75
Association Between PTPN22 Polymorphisms and IgE Responses to Staphylococcal Superantigens in Chronic Urticaria. Allergy Asthma Immunol Res (2014) 0.75
Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review. Front Immunol (2017) 0.75
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell (2006) 33.94
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 30.22
TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity (2006) 29.29
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
Transforming growth factor-beta induces development of the T(H)17 lineage. Nature (2006) 25.91
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 22.89
Functional diversity of helper T lymphocytes. Nature (1996) 18.09
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med (2003) 14.60
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem (2002) 14.34
The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy (2004) 13.16
Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med (1992) 11.90
Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol (2003) 10.21
Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity (2008) 9.82
The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol (2008) 9.64
Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity (2002) 9.29
A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med (2007) 8.97
Plasticity of CD4+ T cell lineage differentiation. Immunity (2009) 8.08
Induction and effector functions of T(H)17 cells. Nature (2008) 7.75
Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol (2008) 6.76
IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol (2008) 6.41
Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med (1989) 6.22
Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol (1999) 6.15
Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol (2000) 5.74
Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol (1999) 5.51
Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature (2006) 5.49
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 5.25
The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol Rev (1988) 5.02
Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med (1999) 4.75
Asthma. N Engl J Med (2009) 4.73
Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol (2004) 4.72
Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med (2006) 4.38
Asthma: an epidemic of dysregulated immunity. Nat Immunol (2002) 4.00
Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science (2002) 3.91
IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol (2001) 3.91
Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet (2007) 3.90
Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med (2004) 3.83
Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet (2008) 3.71
Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis (1990) 3.70
Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol (2003) 3.60
Non-eosinophilic asthma: importance and possible mechanisms. Thorax (2002) 3.53
IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol (1999) 3.52
Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent. J Exp Med (2005) 3.48
Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem (2003) 3.39
IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol (1998) 3.37
Induction of airway mucus production By T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production. J Exp Med (1997) 3.33
Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest (1999) 3.32
Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am J Respir Cell Mol Biol (1994) 3.32
The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol (2003) 3.22
CD4+CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J Exp Med (2005) 3.03
Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. J Allergy Clin Immunol (2003) 2.98
Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat Med (2006) 2.94
Pathogenesis of asthma. Clin Exp Allergy (2008) 2.93
Treatment strategies for allergy and asthma. Nat Rev Immunol (2008) 2.92
Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology (2006) 2.67
IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res (2006) 2.66
Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax (2002) 2.63
IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am J Respir Crit Care Med (2008) 2.62
Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med (1998) 2.55
Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum (2002) 2.54
Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev (2008) 2.52
Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol (2001) 2.39
Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med (2003) 2.26
Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax (2006) 2.18
CD4 T-lymphocyte activation in acute severe asthma. Relationship to disease severity and atopic status. Am Rev Respir Dis (1990) 2.18
Th9 and allergic disease. Immunology (2009) 1.97
Development and function of TH17 cells in health and disease. J Allergy Clin Immunol (2009) 1.95
Innate cells and T helper 2 cell immunity in airway inflammation. Immunity (2009) 1.94
IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells. J Immunol (1998) 1.92
Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am J Respir Cell Mol Biol (1995) 1.92
Increased interleukin-4, interleukin-5, and interferon-gamma in airway CD4+ and CD8+ T cells in atopic asthma. Am J Respir Crit Care Med (2004) 1.88
Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J Exp Med (1997) 1.83
Emerging possibilities in the development and function of regulatory T cells. Int Immunol (2006) 1.82
Th17 and allergy. Allergol Int (2008) 1.80
Regulatory T cells in allergy and asthma. Chest (2007) 1.80
IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol (2000) 1.75
Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med (1994) 1.75
Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med (2002) 1.72
Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation. J Immunol (2008) 1.72
Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med (1998) 1.69
Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells. J Clin Invest (1999) 1.67
Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med (1998) 1.65
The absence of interleukin 9 does not affect the development of allergen-induced pulmonary inflammation nor airway hyperreactivity. J Exp Med (2002) 1.62
TH2 and 'TH2-like' cells in allergy and asthma: pharmacological perspectives. Trends Pharmacol Sci (1994) 1.60
Interleukin-9 promotes allergen-induced eosinophilic inflammation and airway hyperresponsiveness in transgenic mice. Am J Respir Cell Mol Biol (1998) 1.60
Epicutaneous antigen exposure induces a Th17 response that drives airway inflammation after inhalation challenge. Proc Natl Acad Sci U S A (2007) 1.60
Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol (1997) 1.59
Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet (1998) 1.59
Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. J Immunol (2001) 1.55
Elevated release of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma. Am Rev Respir Dis (1993) 1.54
Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 1.52
CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling. J Allergy Clin Immunol (2008) 1.51
Regulatory T cells and asthma. Clin Exp Allergy (2009) 1.48
Mechanisms of immunotherapy. J Allergy Clin Immunol (2004) 1.45
Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes. J Allergy Clin Immunol (2003) 1.43
Mast cell-derived TNF contributes to airway hyperreactivity, inflammation, and TH2 cytokine production in an asthma model in mice. J Allergy Clin Immunol (2007) 1.42
Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness. Thorax (1993) 1.41
Comparison of IL-17 production by helper T cells among atopic and nonatopic asthmatics and control subjects. Int Arch Allergy Immunol (2005) 1.39
Interleukin-17: an emerging role in lung inflammation. Am J Respir Cell Mol Biol (2003) 1.36
Interleukin-17F induces pulmonary neutrophilia and amplifies antigen-induced allergic response. Am J Respir Crit Care Med (2004) 1.31
Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med (2008) 3.67
Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain. Infect Immun (2005) 1.97
Matrix metalloproteinase 9 activity enhances host susceptibility to pulmonary infection with type A and B strains of Francisella tularensis. J Immunol (2007) 1.85
Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection. Infect Immun (2007) 1.64
Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol (2007) 1.61
Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect Immun (2007) 1.57
Type I IFN signaling constrains IL-17A/F secretion by gammadelta T cells during bacterial infections. J Immunol (2010) 1.52
Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis. Immunol Rev (2008) 1.48
Early activation of NK cells after lung infection with the intracellular bacterium, Francisella tularensis LVS. Cell Immunol (2005) 1.47
Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J Immunol (2010) 1.38
Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol (2008) 1.36
An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine (2008) 1.35
Superoxide dismutase B gene (sodB)-deficient mutants of Francisella tularensis demonstrate hypersensitivity to oxidative stress and attenuated virulence. J Bacteriol (2006) 1.33
Adaptation of Francisella tularensis to the mammalian environment is governed by cues which can be mimicked in vitro. Infect Immun (2008) 1.25
Two DHH subfamily 1 proteins in Streptococcus pneumoniae possess cyclic di-AMP phosphodiesterase activity and affect bacterial growth and virulence. J Bacteriol (2013) 1.24
A detrimental effect of interleukin-10 on protective pulmonary humoral immunity during primary influenza A virus infection. J Virol (2010) 1.22
Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS One (2011) 1.20
Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun (2003) 1.19
Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol (2003) 1.16
Cyclic di-AMP impairs potassium uptake mediated by a cyclic di-AMP binding protein in Streptococcus pneumoniae. J Bacteriol (2013) 1.16
Generation and characterization of an attenuated mutant in a response regulator gene of Francisella tularensis live vaccine strain (LVS). DNA Cell Biol (2008) 1.14
Identification of Francisella tularensis live vaccine strain CuZn superoxide dismutase as critical for resistance to extracellularly generated reactive oxygen species. J Bacteriol (2009) 1.05
Rational design of pathogen-mimicking amphiphilic materials as nanoadjuvants. Sci Rep (2011) 1.03
The Th2-restricted immune response to xenogeneic small intestinal submucosa does not influence systemic protective immunity to viral and bacterial pathogens. Tissue Eng (2002) 1.02
Development of allergen-induced airway inflammation in the absence of T-bet regulation is dependent on IL-17. J Immunol (2009) 1.01
An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage. J Immunol (2004) 0.98
Identification of a novel Francisella tularensis factor required for intramacrophage survival and subversion of innate immune response. J Biol Chem (2012) 0.97
Influenza infection suppresses NADPH oxidase-dependent phagocytic bacterial clearance and enhances susceptibility to secondary methicillin-resistant Staphylococcus aureus infection. J Immunol (2014) 0.97
Natural anti-galactose alpha1,3 galactose antibodies delay, but do not prevent the acceptance of extracellular matrix xenografts. Transpl Immunol (2002) 0.97
Exogenous interleukin-12 protects against lethal infection with coxsackievirus B4. J Virol (2003) 0.96
Immune response to small intestinal submucosa (surgisis) implant in humans: preliminary observations. J Invest Surg (2007) 0.93
Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia. Vaccine (2011) 0.90
The vitamin B₆ biosynthesis pathway in Streptococcus pneumoniae is controlled by pyridoxal 5'-phosphate and the transcription factor PdxR and has an impact on ear infection. J Bacteriol (2013) 0.90
Contribution of citrulline ureidase to Francisella tularensis strain Schu S4 pathogenesis. J Bacteriol (2009) 0.88
Analysis of murine genetic predisposition to pneumococcal infection reveals a critical role of alveolar macrophages in maintaining the sterility of the lower respiratory tract. Infect Immun (2011) 0.87
Increased susceptibility of IgA-deficient mice to pulmonary Francisella tularensis live vaccine strain infection. Infect Immun (2013) 0.87
Mucosal B cell deficiency in IgA-/- mice abrogates the development of allergic lung inflammation. J Immunol (2005) 0.86
Cyclic pressure affects osteoblast functions pertinent to osteogenesis. Ann Biomed Eng (2003) 0.86
Identification of a live attenuated vaccine candidate for tularemia prophylaxis. PLoS One (2013) 0.85
Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media. Vaccine (2006) 0.85
Deletion of arcD in Streptococcus pneumoniae D39 impairs its capsule and attenuates virulence. Infect Immun (2013) 0.84
Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins. J Virol (2003) 0.84
Intranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue. Vaccine (2008) 0.84
Galectin-3 functions as an alarmin: pathogenic role for sepsis development in murine respiratory tularemia. PLoS One (2013) 0.83
Antistaphylococcal nanocomposite films based on enzyme-nanotube conjugates. ACS Nano (2010) 0.83
Mouse models for the study of mucosal vaccination against otitis media. Vaccine (2008) 0.83
Effects of cyclic pressure on bone marrow cell cultures. J Biomech Eng (2002) 0.82
IL-12 as an adjuvant for the enhancement of protective humoral immunity. Expert Rev Vaccines (2009) 0.81
Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague. Clin Vaccine Immunol (2011) 0.79
Azithromycin modulates murine immune responses to pneumococcal conjugate vaccine and inhibits nasal clearance of bacteria. J Infect Dis (2004) 0.77
Immunological concerns with bioengineering approaches. Ann N Y Acad Sci (2002) 0.76
Use and misuse of statistical significance in survival analyses. MBio (2014) 0.75
Immune response to engineered tissues and cells: breakout session summary. Ann N Y Acad Sci (2002) 0.75